Immunovia AB (publ) announced according to the instructions for the nomination committee of the company that were adopted at the Annual General Meeting on May 26, 2023, the nomination committee shall consist of four members. The nomination committee, which is to be appointed for the period until a new nomination committee is appointed, shall consist of four members, of which three will be appointed by the company's three largest shareholders in terms of voting, and the fourth shall be the Chair of the board of directors. If the chair of the board of directors is one of the three largest shareholders, he shall, in his/her capacity as shareholder, make his seat available and the next shareholder shall be offered the right to appoint a member to the nomination committee.

Based on the nomination committee has been determined to consist of the following persons who together represent 7.52% of the number of shares and votes in the company as of September 30, 2023: Carl Borrebaeck, representing Carl Borrebaeck; Mats Leifland, representing Mats Ohlin; Sara Ek, representing Sara Ek appointed Chair of the nomination Committee.